Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K R Lees

Showing results (81-90 of 197) with videos related to

Pageof 20
Sort By:
International Journal of Stroke : Official Journal of the International Stroke Society|August 8, 2009
Functional outcome measures in contemporary stroke trialsT J Quinn, J Dawson, M R Walters, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|January 22, 2010
Patient outcomes in historical comparators compared with randomised-controlled trialsM Ali, E Jüttler, K R Lees, et al.
British Journal of Clinical Pharmacology|July 15, 1998
Determinants of the blood pressure response to the first dose of ACE inhibitor in mild to moderate congestive heart failureL Murray, I B Squire, J L Reid, et al.
Lancet (London, England)|August 13, 1994
Anticardiolipin antibodies in an unselected stroke populationK W Muir, I B Squire, W Alwan, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1988
Indirect assessment of tissue angiotensin II converting enzyme inhibition in vivo in manK R Lees, A W Kelman, B Whiting, et al.
Brain Research|November 21, 1994
Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the catP E Bannan, D I Graham, K R Lees, et al.
Lancet (London, England)|August 28, 1993
Clinical significance of cerebral emboli signalsD G Grosset, D Georgiadis, W S Hillis, et al.
Journal of Pharmacokinetics and Biopharmaceutics|October 1, 1989
Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue bindingK R Lees, A W Kelman, J L Reid, et al.
British Journal of Clinical Pharmacology|July 1, 1994
Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteersK W Muir, D G Grosset, E Gamzu, et al.
Lancet (London, England)|February 16, 2000
Treatment and secondary prevention of strokeJ R Overell, C J Weir, A Walker, et al.
Pageof 20

Showing results (81-90 of 197) with videos related to

Sort By:
Pageof 20
International Journal of Stroke : Official Journal of the International Stroke Society|August 8, 2009
Functional outcome measures in contemporary stroke trialsT J Quinn, J Dawson, M R Walters, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|January 22, 2010
Patient outcomes in historical comparators compared with randomised-controlled trialsM Ali, E Jüttler, K R Lees, et al.
British Journal of Clinical Pharmacology|July 15, 1998
Determinants of the blood pressure response to the first dose of ACE inhibitor in mild to moderate congestive heart failureL Murray, I B Squire, J L Reid, et al.
Lancet (London, England)|August 13, 1994
Anticardiolipin antibodies in an unselected stroke populationK W Muir, I B Squire, W Alwan, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1988
Indirect assessment of tissue angiotensin II converting enzyme inhibition in vivo in manK R Lees, A W Kelman, B Whiting, et al.
Brain Research|November 21, 1994
Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the catP E Bannan, D I Graham, K R Lees, et al.
Lancet (London, England)|August 28, 1993
Clinical significance of cerebral emboli signalsD G Grosset, D Georgiadis, W S Hillis, et al.
Journal of Pharmacokinetics and Biopharmaceutics|October 1, 1989
Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue bindingK R Lees, A W Kelman, J L Reid, et al.
British Journal of Clinical Pharmacology|July 1, 1994
Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteersK W Muir, D G Grosset, E Gamzu, et al.
Lancet (London, England)|February 16, 2000
Treatment and secondary prevention of strokeJ R Overell, C J Weir, A Walker, et al.
Pageof 20